tiprankstipranks
Trending News
More News >
OssDsign AB (SE:OSSD)
:OSSD
Sweden Market

OssDsign AB (OSSD) AI Stock Analysis

Compare
1 Followers

Top Page

SE:OSSD

OssDsign AB

(OSSD)

Select Model
Select Model
Select Model
Neutral 50 (OpenAI - 4o)
Rating:50Neutral
Price Target:
kr11.00
▼(-2.65% Downside)
OssDsign AB's overall stock score is primarily influenced by its financial performance and technical analysis. The company's strong revenue growth and gross margin improvements are overshadowed by persistent losses and negative cash flows. Technical indicators suggest a bearish trend, and valuation metrics reflect the company's unprofitability. The absence of earnings call data and corporate events limits additional insights.
Positive Factors
Revenue Growth
Strong revenue growth indicates robust demand for OssDsign's products and effective market penetration, supporting long-term business expansion.
Gross Margin Improvement
High gross margins suggest effective cost management and pricing power, enhancing profitability potential as the company scales.
Solid Equity Base
A strong equity base provides financial stability and flexibility, enabling OssDsign to invest in growth opportunities and withstand economic fluctuations.
Negative Factors
Unprofitability
Continued unprofitability can hinder long-term sustainability, requiring strategic adjustments to achieve break-even and profitability.
Negative Cash Flows
Negative cash flows can strain liquidity and limit the company's ability to fund operations and growth without external financing.
Negative Return on Equity
Negative return on equity indicates inefficiency in generating returns from shareholders' investments, potentially affecting investor confidence.

OssDsign AB (OSSD) vs. iShares MSCI Sweden ETF (EWD)

OssDsign AB Business Overview & Revenue Model

Company DescriptionOssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally. The company's products include OSSDSIGN cranial, an implant solution and related accessories for skull defect reconstruction in cranioplasty patients; and OSSDSIGN facial to treat post-traumatic skeletal deformities and congenital skeletal defects. It also offers OSSDSIGN Cranioplug for bone flap fixation and burr hole coverage; and OssDsign Catalyst, a nanosynthetic bone graft substitute that stimulates the formation of healthy bone tissue. The company was incorporated in 2011 and is headquartered in Uppsala, Sweden.
How the Company Makes MoneyOssDsign AB generates revenue through the sale of its proprietary biomaterial implants and related products in the medical field. The company primarily earns income from hospitals and surgical centers that purchase its custom implants for use in surgical procedures. Key revenue streams include direct sales of their products, which are often billed to healthcare providers or insurance companies, as well as potential royalties from partnerships with larger medical device companies that may license OssDsign's technology. Additionally, the company may benefit from collaborations with research institutions and participation in clinical trials, which can enhance its market presence and drive further sales.

OssDsign AB Financial Statement Overview

Summary
OssDsign AB is experiencing strong revenue growth and improved gross margins, indicating potential for future profitability. However, persistent losses and negative cash flows are significant challenges. The company benefits from a strong equity base and low leverage, providing some financial stability.
Income Statement
OssDsign AB has shown significant revenue growth over the years, with a CAGR of approximately 35% from 2019 to 2024. The company has improved its gross profit margin, reaching 95.38% in 2024, indicating strong pricing power or cost control. However, the company remains unprofitable, with a net profit margin of -37.07% in 2024, and EBIT and EBITDA margins also remain negative. The trend of narrowing losses suggests potential for future profitability if the trajectory continues.
Balance Sheet
The company maintains a strong equity position with an equity ratio of 69.61% in 2024, indicating a solid capital structure. The debt-to-equity ratio is low at 0.009, showcasing low financial leverage. Despite this, the consistent negative net income impacts return on equity, which remains negative. The company has a sizable cash position, which provides financial flexibility.
Cash Flow
OssDsign AB's cash flows remain challenging, with substantial negative operating cash flow and free cash flow in 2024. The operating cash flow to net income ratio is negative, indicating cash outflows exceed losses. However, the free cash flow improved slightly compared to 2023, suggesting some operational improvements. Continued negative cash flows could pose liquidity risks if not addressed.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue176.48M133.94M112.16M56.98M31.73M24.87M
Gross Profit170.12M127.75M83.64M45.13M20.84M16.00M
EBITDA-37.43M-45.31M-122.02M-89.41M-79.97M-80.64M
Net Income-41.76M-49.66M-130.49M-99.39M-93.92M-84.59M
Balance Sheet
Total Assets430.71M307.42M356.39M339.50M343.99M246.65M
Cash, Cash Equivalents and Short-Term Investments210.86M100.86M165.94M124.65M151.37M49.40M
Total Debt1.64M1.97M3.15M13.60M14.13M17.24M
Total Liabilities83.43M93.36M105.26M91.39M81.26M134.58M
Stockholders Equity347.27M214.06M251.13M248.11M262.72M112.07M
Cash Flow
Free Cash Flow-57.88M-63.04M-94.03M-89.36M-89.84M-81.59M
Operating Cash Flow-54.18M-62.38M-93.91M-89.23M-89.78M-79.10M
Investing Cash Flow-5.16M-657.00K-124.00K-129.00K-51.85M-17.67M
Financing Cash Flow161.74M-2.46M135.40M61.84M243.43M33.18M

OssDsign AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price11.30
Price Trends
50DMA
11.43
Negative
100DMA
12.94
Negative
200DMA
13.31
Negative
Market Momentum
MACD
-0.25
Positive
RSI
37.74
Neutral
STOCH
14.72
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:OSSD, the sentiment is Negative. The current price of 11.3 is below the 20-day moving average (MA) of 11.57, below the 50-day MA of 11.43, and below the 200-day MA of 13.31, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 37.74 is Neutral, neither overbought nor oversold. The STOCH value of 14.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:OSSD.

OssDsign AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
kr1.09B46.676.93%-5.80%-65.99%
52
Neutral
kr1.27B200.521.41%21.71%-80.37%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
kr1.16B-25.5038.43%57.76%
48
Neutral
kr983.44M-24.19-4.42%13.48%28.98%
46
Neutral
kr613.27M-28.83-6.81%-8.10%62.08%
43
Neutral
kr806.51M-5.92-36.55%62.24%21.16%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:OSSD
OssDsign AB
10.50
-0.66
-5.91%
SE:PAX
Paxman AB
54.40
-17.40
-24.23%
SE:SEZI
Senzime AB
5.13
-0.91
-15.07%
SE:BACTI.B
Bactiguard Holding AB
17.50
-17.80
-50.42%
SE:CRAD.B
C-Rad AB Class B
32.20
3.20
11.03%
SE:SEDANA
Sedana Medical AB
9.90
-5.60
-36.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 05, 2025